Takeda Recognized in the 2019 Dow Jones Sustainability World Index
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was named for the 10th consecutive year in the Dow Jones Sustainability Asia Pacific Index. The Dow Jones Sustainability Indices are an independent indication of the Company’s strong corporate environmental, social and governance (ESG) performance.
“Takeda’s commitment to creating and preserving value through environmental, social and governance initiatives is an important part of our role as a patient-centric and values-based global biopharmaceutical leader,” said Christophe Weber, President and CEO. “We understand the significance of sustainable business practices, and we are proud to be recognized for Takeda’s global impact and long-term commitment to building a brighter future.”
Takeda achieved more than double the average pharmaceutical industry sustainability score. Its strong scores in climate strategy and eco-efficiency support Takeda’s approach that a proactive environmental program focused on reducing environmental impacts leads to tangible economic benefits. Takeda also achieved double-digit year-over-year growth in its score for access to medicines – more than triple the industry average – based on its strategies to help strengthen evolving healthcare systems and tackle barriers that limit patient access.
In addition to Dow Jones World and Asia Pacific Indices, Takeda has been selected by multiple benchmark ESG indices and recognitions:
|
Name of
|
Company/
|
Country |
History of
|
|
FTSE4Good Developed Index |
FTSE Russell |
UK |
15th consecutive year |
|
MSCI ESG Leaders Index |
MSCI |
U.S. |
10th consecutive year |
|
Ethibel EXCELLENCE Investment
|
Forum Ethibel |
BEL |
From July 2017 |
|
Prime Status |
ISS-Oekom |
GER |
2nd consecutive year |
|
Industry Mover Sustainability Yearbook
|
RobecoSAM |
CHE |
From February 2019 |
|
Global 100 Most Sustainable
|
Corporate Knights |
CND |
4th consecutive year |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit www.takeda.com
About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190918006069/en/
Contact information
Media Contact:
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest Launches Professional Services to Elevate Quality Engineering Excellence20.9.2024 18:00:00 EEST | Press release
LambdaTest, a leading cloud-based unified testing platform, officially introduced its Professional Services, designed to transform how organizations achieve quality engineering excellence. This service offers a comprehensive suite of end-to-end testing solutions, powered by AI-driven technology, ensuring maximum test coverage, optimized test scripts, and seamless framework migrations. The newly launched services address key challenges enterprises face today—enhancing testing efficiency, increasing coverage, and reducing bottlenecks in QA. LambdaTest Professional Services also offers tailored test suite development, ensuring that organizations can craft custom solutions suited to their specific needs, while ongoing efficiency maintenance ensures long-term performance and quality. With flexible pricing plans that scale as per business needs, LambdaTest’s Professional Services are built for agility, making it easier for businesses of any size to implement robust testing frameworks and sta
Alvaria’s Workforce Enterprise Suite Becomes Aspect20.9.2024 16:00:00 EEST | Press release
Alvaria, a pioneer in workforce management and contact center customer experience technology, servicing large global enterprises and rapidly growing consumer brands, announced the rebirth of Aspect in response to accelerated company growth and a demand for more complex tools to support hybrid, remote and in-person workforces. Aspect encapsulates Alvaria’s Enterprise Workforce Suite and will operate as an Alvaria-owned subsidiary. Aspect returns to the brand portfolio with a modern and innovative suite of products, including their new next-generation platform, WorkforceOS, powered by predictive analytics and a mission to humanize the service economy. Aspect has a rich history of innovation and leadership in the contact center space, having pioneered the world’s first Automatic Call Distribution (ACD) and the first Workforce Management Software for contact centers. Alvaria has named Darryl Kelly as Chief Executive Officer to steward this brand evolution. Kelly, an accomplished senior lea
Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase20.9.2024 15:00:00 EEST | Press release
Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases advancements in open optical networking and innovative vendor-neutral solutions, highlighting the importance of testing multi-vendor interoperability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920990844/en/ Adtran’s central role in the OIF demo underlines its commitment to developing open solutions that seamlessly interoperate with other ve
Matchday Champions , a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept20.9.2024 14:00:00 EEST | Press release
Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept. Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have already pre-registered ahead of launch. Matchday Champions is now available in early access globally for iOS and Android phones. Players who download the ga
Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy20.9.2024 11:12:00 EEST | Press release
Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India to clinical trials in the USA, for approval by FDA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920153092/en/ The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he fou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom